title: The interruption of PKC-ι signaling and TRAIL combination therapy against glioblastoma cells.
abstract: Glioblastoma is a highly aggressive type of brain cancer which currently has limited options for treatment. It is imperative to develop combination therapies that could cause apoptosis in glioblastoma. The aim of this study was to characterize the affect of modified ICA-1, a PKC-iota inhibitor, on the growth pattern of various glioblastoma cell lines. T98G and U87 glioblastoma cells were treated with ICA-1 alone and the absolute cell numbers of each group were determined for cell growth expansion analysis, cell viability analysis, and cell death analysis. Low dose ICA-1 treatment alone significantly inhibited cell growth expansion of high density glioblastoma cells without inducing cell death. However, the high dose ICA-1 treatment regimen provided significant apoptosis for glioblastoma cells. Furthermore, this study was conducted to use a two layer molecular level approach for treating glioblastoma cells with ICA-1 plus an apoptosis agent, tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL), to induce apoptosis in such chemo-refractory cancer cells. Following ICA-1 plus TRAIL treatment, apoptosis was detected in glioblastoma cells via the TUNEL assay and via flow cytometric analysis using Annexin-V FITC/PI. This study offers the first evidence for ICA-1 alone to inhibit glioblastoma cell proliferation as well as the novel combination of ICA-1 with TRAIL to cause robust apoptosis in a caspase-3 mediated mechanism. Furthermore, ICA-1 plus TRAIL simultaneously modulates down-regulation of PKC-iota and c-Jun.
authors: James A. Haley Veterans' Hospital, 13000 Bruce B. Downs Blvd., VAR 151, Tampa, FL, 33612, USA, Andrea.Mccray2@va.gov.
authors: Andrea N
authors: AN
authors: McCray
authors: Shraddha
authors: S
authors: Desai
authors: Mildred
authors: M
authors: Acevedo-Duncan
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D005909:Glioblastoma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010755:Organophosphates / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism; D015398:Signal Transduction; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000494:pharmacology / Q000627:therapeutic use*; D000099293:Protein Kinase C-lambda
chemical_list: D053148:Caspase 3; D007093:Imidazoles; D007527:Isoenzymes; D010755:Organophosphates; D011493:Protein Kinase C; D016755:Proto-Oncogene Proteins c-jun; D053221:TNF-Related Apoptosis-Inducing Ligand; D000099293:Protein Kinase C-lambda; C559837:(4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-dihydroxycyclopentyl) methyl phosphate; C505653:TNFSF10 protein, human